Research Type: Reports

We conduct thorough investigations and studies of related various aspects of drug prices. When concluded, they are published to share our findings with academic, policymakers, and the public.

  • Remdesivir Less Expensive for “Government Programs”? Not So Fast.

    Remdesivir Less Expensive for “Government Programs”? Not So Fast.

  • Blueprints for Indication-Specific Pricing

    Blueprints for Indication-Specific Pricing

  • Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries

  • Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

    Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

  • Overview of Original Subscription Model and Features of LA and WA Proposals

    Overview of Original Subscription Model and Features of LA and WA Proposals

  • DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)

  • DPL responds to HHS Blueprint (May 16, 2018)

  • Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold

    Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold

  • Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?

    Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?

  • Copay Assistance: The Epipen Example

    Copay Assistance: The Epipen Example